Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Calcium chloride + magnesium chloride + dextrose monohydrate + sodium chloride + sodium lactate** is a multi-electrolyte **peritoneal dialysis solution** marketed under the brand **DELFLEX** for the treatment of **chronic kidney failure** in patients maintained on peritoneal dialysis. It is a sterile, non-pyrogenic aqueous solution administered **intraperitoneally**, not intravenously. **Dextrose monohydrate** functions as the principal osmotic agent, creating an osmotic gradient across the peritoneal membrane to promote ultrafiltration and removal of excess water and uremic solutes, while **sodium, chloride, lactate, calcium, and magnesium** help maintain electrolyte and acid-base balance during dialysis. DELFLEX is available in multiple dextrose strengths and electrolyte compositions, including low magnesium and low calcium variants; the product was initially approved in the United States in **1984**, with a low magnesium/low calcium formulation approved in **1992**.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium chloride + magnesium chloride + dextrose monohydrate + sodium chloride + sodium lactate.